Detalles del proyecto
| Estado | Finalizado |
|---|---|
| Fecha de inicio/Fecha fin | 8/1/05 → 6/30/12 |
Financiación
- Virxsys Corporation: 54.316,00 US$
A Phase II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Biological Activity of Repeated doses of Autologous T Cells Transduced with VRX496 in HIV-Positive Subjects
- Greenberg, Richard (PI)